10x Genomics, Inc. (TXG)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue TTM

0 250M 500M 750M Q4 '18: 146.3M Q1 '19: 172.5M Q2 '19: 196.6M Q3 '19: 221.2M Q4 '19: 245.9M Q1 '20: 264.2M Q2 '20: 251.3M Q3 '20: 261.9M Q4 '20: 298.8M Q1 '21: 332.8M Q2 '21: 405.7M Q3 '21: 459.2M Q4 '21: 490.5M Q1 '22: 499.2M Q2 '22: 497.9M Q3 '22: 503.7M Q4 '22: 516.4M Q1 '23: 536.2M Q2 '23: 568.4M Q3 '23: 591M Q4 '23: 618.7M Q1 '24: 625.4M Q2 '24: 631.7M Q3 '24: 629.7M Q4 '24: 610.8M Q1 '25: 624.7M Q2 '25: 644.5M Q3 '25: 641.8M Q4 '25: 642.8M Q1 '26: 638.8M Q2 '26: 616.9M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Gross Profit TTM

0 200M 400M 600M Q4 '18: 117.7M Q1 '19: 133.8M Q2 '19: 147.4M Q3 '19: 161.8M Q4 '19: 184.9M Q1 '20: 202M Q2 '20: 194.1M Q3 '20: 205.8M Q4 '20: 240.4M Q1 '21: 272.3M Q2 '21: 350.4M Q3 '21: 393.8M Q4 '21: 416.4M Q1 '22: 416.7M Q2 '22: 392.6M Q3 '22: 392.6M Q4 '22: 396M Q1 '23: 405.4M Q2 '23: 418.1M Q3 '23: 412.9M Q4 '23: 409.3M Q1 '24: 403.8M Q2 '24: 408.4M Q3 '24: 419.3M Q4 '24: 414.5M Q1 '25: 427M Q2 '25: 447.9M Q3 '25: 441.8M Q4 '25: 443.9M Q1 '26: 444.6M Q2 '26: 432M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Operating Income TTM

-600M -400M -200M 0 200M 400M 600M Q2 '19: -103.3M Q3 '19: -97.5M Q4 '19: -30.6M Q1 '20: -47.4M Q2 '20: -76.5M Q3 '20: -132.6M Q4 '20: -534.1M Q1 '21: -524.5M Q2 '21: -495.4M Q3 '21: -446M Q4 '21: -52.3M Q1 '22: -83.8M Q2 '22: -136.6M Q3 '22: -160.7M Q4 '22: -167.9M Q1 '23: -178.2M Q2 '23: -178.4M Q3 '23: -233.2M Q4 '23: -265.3M Q1 '24: -274.8M Q2 '24: -253.2M Q3 '24: -199.9M Q4 '24: -194.6M Q1 '25: -172.4M Q2 '25: -100.5M Q3 '25: -91.3M Q4 '25: -61M Q1 '26: -38.7M Q2 '26: -88.4M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Net Income TTM

-600M -400M -200M 0 200M 400M 600M Q4 '18: -112.5M Q1 '19: -100.4M Q2 '19: -105.4M Q3 '19: -99.6M Q4 '19: -31.3M Q1 '20: -48.8M Q2 '20: -78M Q3 '20: -134.3M Q4 '20: -542.7M Q1 '21: -533.1M Q2 '21: -504M Q3 '21: -455.3M Q4 '21: -58.2M Q1 '22: -89.1M Q2 '22: -142.5M Q3 '22: -167.2M Q4 '22: -166M Q1 '23: -174.3M Q2 '23: -172.3M Q3 '23: -223.4M Q4 '23: -255.1M Q1 '24: -264.3M Q2 '24: -239.8M Q3 '24: -182.6M Q4 '24: -182.6M Q1 '25: -157M Q2 '25: -84.6M Q3 '25: -76.3M Q4 '25: -43.5M Q1 '26: -22.7M Q2 '26: -75.1M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Cost of Revenue TTM

0 80M 160M 240M Q2 '19: 49.1M Q3 '19: 59.4M Q4 '19: 61M Q1 '20: 62.2M Q2 '20: 57.2M Q3 '20: 56.2M Q4 '20: 58.5M Q1 '21: 60.4M Q2 '21: 55.3M Q3 '21: 65.4M Q4 '21: 74.1M Q1 '22: 82.5M Q2 '22: 105.3M Q3 '22: 111.2M Q4 '22: 120.4M Q1 '23: 130.8M Q2 '23: 150.3M Q3 '23: 178M Q4 '23: 209.4M Q1 '24: 221.6M Q2 '24: 223.3M Q3 '24: 210.4M Q4 '24: 196.3M Q1 '25: 197.6M Q2 '25: 196.6M Q3 '25: 200M Q4 '25: 198.9M Q1 '26: 194.2M Q2 '26: 184.9M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Operating Cash Flow TTM

-240M -160M -80M 0 80M 160M 240M Q3 '19: -23.1M Q4 '19: 34.6M Q1 '20: 22.7M Q2 '20: -10.9M Q3 '20: -81M Q4 '20: -217.9M Q1 '21: -219.4M Q2 '21: -186.8M Q3 '21: -157.4M Q4 '21: -21.4M Q1 '22: -38.1M Q2 '22: -58.2M Q3 '22: -41.5M Q4 '22: -33.6M Q1 '23: -16.9M Q2 '23: -11.5M Q3 '23: -27.2M Q4 '23: -15.2M Q1 '24: -26.8M Q2 '24: -7.8M Q3 '24: 39.2M Q4 '24: 6.7M Q1 '25: 56.7M Q2 '25: 67M Q3 '25: 88.5M Q4 '25: 136.1M Q1 '26: 127.8M Q2 '26: 127.1M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Free Cash Flow TTM

-300M -200M -100M 0 100M 200M 300M Q3 '19: -61.7M Q4 '19: -8.1M Q1 '20: -18.7M Q2 '20: -45.9M Q3 '20: -102.9M Q4 '20: -254.6M Q1 '21: -286.9M Q2 '21: -262M Q3 '21: -252.4M Q4 '21: -122.7M Q1 '22: -128.6M Q2 '22: -161.4M Q3 '22: -161.1M Q4 '22: -165.3M Q1 '23: -125M Q2 '23: -117.7M Q3 '23: -112.1M Q4 '23: -63.8M Q1 '24: -73.7M Q2 '24: -32.2M Q3 '24: 26M Q4 '24: -5.7M Q1 '25: 45.4M Q2 '25: 56.9M Q3 '25: 81.7M Q4 '25: 130.1M Q1 '26: 122.2M Q2 '26: 121.4M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 50M 100M 150M Q1 '20: 96.8M Q2 '20: 99M Q3 '20: 101.3M Q1 '21: 108.7M Q2 '21: 109.9M Q3 '21: 110.9M Q1 '22: 113M Q2 '22: 113.6M Q3 '22: 114.1M Q1 '23: 115.6M Q2 '23: 116.7M Q3 '23: 117.7M Q1 '24: 119.4M Q2 '24: 120.1M Q3 '24: 120.7M Q1 '25: 122.6M Q2 '25: 124.5M Q3 '25: 125.5M Q1 '26: 128.3M Q2 '26: 130M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-9.00 -6.00 -3.00 0.00 3.00 6.00 9.00 Q4 '18: -8.21 Q1 '19: -7.23 Q2 '19: -7.48 Q3 '19: -6.68 Q4 '19: -1.35 Q1 '20: -1.32 Q2 '20: -1.03 Q3 '20: -1.35 Q4 '20: -5.37 Q1 '21: -5.26 Q2 '21: -4.95 Q3 '21: -4.45 Q4 '21: -0.53 Q1 '22: -0.80 Q2 '22: -1.27 Q3 '22: -1.49 Q4 '22: -1.47 Q1 '23: -1.53 Q2 '23: -1.49 Q3 '23: -1.91 Q4 '23: -2.17 Q1 '24: -2.23 Q2 '24: -2.02 Q3 '24: -1.53 Q4 '24: -1.53 Q1 '25: -1.31 Q2 '25: -0.71 Q3 '25: -0.63 Q4 '25: -0.35 Q1 '26: -0.17 Q2 '26: -0.59 Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.